参考文献/References:
[1]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin,2019, 69(1):7-34.
[2]Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs.4th eds. Lyon: IARC Press,2014.8-253.
[3]Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol,2016,27(Suppl1):i53-i57.
[4]Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol,2010,171(1):45-53.
[5]Morice P, Gouy S, Leary A. Mucinous ovarian carcinoma. N Engl J Med,2019,380(13):1256-1266.
[6]Bassiouny D, Ismiil N, Dubé V, et al. Comprehensive clinicopathologic and updated immunohistochemical characterization of primary ovarian mucinous carcinoma. Int J Surg Pathol,2018,26(4):306-317.
[7]Prat J, D’Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol,2018, 80:11-27.
[8]Affatato R, Carrassa L, Chilà R, et al. Identification of PLK1 as a new therapeutic target in mucinous ovarian carcinoma. Cancers (Basel),2020,12(3):672.
[9]Zhang GH, Chen MM, Kai JY, et al. Molecular profiling of mucinous epithelial ovarian cancer by weighted gene coexpression network analysis. Gene,2019,709:56-64.
[10]Cheasley D, Wakefield MJ, Ryland GL, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun,2019,10(1):3935.
[11]Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol,2009,113(3):331-334.
[12]Tuxen MK, Slétormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev,1995,21(3):215-245.
[13]National Comprehensive Cancer Network. NCCN Guideline in Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer (Version 1.2020). Fort Washington: NCCN,2020.
[14]Wagner V, Winn H, Newtson A, et al. hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman. Gynecol Oncol Rep,2018,26:102-104.
[15]Crane EK, Brown J. Early stage mucinous ovarian cancer: a review. Gynecol Oncol, 2018,149(3):598-604.
[16]Nasioudis D, Albright BB, Ko EM, et al. Advanced stage primary mucinous ovarian carcinoma. Where do we stand? Arch Gynecol Obstet,2020,301(4):1047-1054.
[17]Bamias A, Sotiropoulou M, Zagouri F, et al. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. Eur J Cancer,2012,48(10):1476-1483.
[18]Yoshihara M, Kajiyama H,Tamauchi S, et al. Impact of uteruspreserving surgery on stageⅠprimary mucinous epithelial ovarian carcinoma: A multiinstitutional study with propensity scoreweighted analysis. Int J Gynaecol Obstet,2020,150(2):177-183.
[19]Gouy S, Saidani M, Maulard A, et al. Staging surgery in earlystage ovarian mucinous tumors according to expansile and infiltrative types. Gynecol Oncol Rep,2017,22:21-25.
[20]Hoogendam JP, Vlek CA, Witteveen PO, et al. Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and metaanalysis. BJOG,2017,124(3):370-378.
[21]Rosendahl M, Haueberg Oester LA, Hgdall CK. The importance of appendectomy in surgery for mucinous adenocarcinoma of the ovary. Int J Gynecol Cancer,2017,27(3):430-436.
[22]Cheng A, Li M, Kanis MJ, et al. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and metaanalysis. Gynecol Oncol,2017,144(1):215-222.
[23]马静波.腹腔镜与开腹手术治疗早期(Ⅰ～Ⅱ期)卵巢癌有效性、安全性的对比研究.腹腔镜外科杂志,2019,24(2):147-151.
[24]柳禹,曹莉莉,周莉,等.晚期上皮性卵巢癌经腹腔镜和开腹的初次肿瘤细胞减灭术或中间型减瘤术的临床对比研究.实用妇产科杂志,2020,36(4):298-302.
[25]王永军,韩肖彤,王建六.腹腔镜联合开腹肿瘤细胞减灭术在复发性卵巢癌中的应用(附2例报告).中国微创外科杂志,2018,18(2):181-183.
[26]Bamias A, Sotiropoulou M, Zagouri F, et al. Prognostic evaluation of tumourtypeand other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. Eur J Cancer,2012,48(10):1476-1483.
[27]Nasioudis D, Haggerty AF, Giuntoli RL, et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma. Gynecol Oncol,2019,154(2):302-307.
[28]Kurnit KC, Sinno AK, Fellman BM, et al. Effects of gastrointestinaltype chemotherapy in women with ovarian mucinous carcinoma. Obstet Gynecol,2019,134(6):1253-1259.
[29]Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med,2018,378(3):230-240.
[30]Wu QW, Wu QQ, Xu J, et al. Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: a metaanalysis. Int J Hyperthermia,2019,36(1):562-572.
[31]Zhang G, Zhu Y, Liu C, et al. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the metaanalysis. J Ovarian Res,2019,12(1):33.
[32]Mercier F, Bakrin N, Bartlett DL, et al. Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multiinstitutional cohort from PSOGI and BIGRENAPE. Ann Surg Oncol,2018,25(6):1668-1675.
[33]Gorringe KL, Cheasley D, Wakefield MJ, et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol,2020,156(3):552-560.
[34]Momeny M, Sabourinejad Z, Zarrinrad G, et al. Antitumour activity of tivozanib, a paninhibitor of VEGF receptors, in therapyresistant ovarian carcinoma cells. Sci Rep,2017,7:45954.
[35]PujadeLauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinumresistant recurrent ovarian cancer: The AURELIA openlabel randomized phase Ⅲ trial. J Clin Oncol,2014,32(13):1302-1308.
[36]Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: Roles in precision medicine. Semin Cancer Biol,2019,59:23-35.
[37]Sato N, Saga Y, Mizukami H, et al. Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncol Rep,2012,27(5):1336-1340.
[38]Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol,2013,229(1):111-120.
[39]McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer,2009,9:433.
[40]Bridges KA, Chen X, Liu H, et al.MK8776, a novel chk1 kinase inhibitor, radiosensitizes p53defective human tumor cells. Oncotarget,2016,7(44):71660-71672.
[41]Liu T, Hu W, Dalton HJ, et al. Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res,2013,19(23):6532-6543.
[42]Inaba K, Oda K, Aoki K, et al. Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.Oncotarget,2016,7(20):29577-29591.
[43]Geng F, Wang Z, Yin H, et al. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives. Cancer Biother Radiopharm,2017,32(5):149-160.